Home

Skyline Venture Partners Qualified Purchaser Fund IV L P

CIK 1324617 · last filed 2014-02-21

Skyline Venture Partners Qualified Purchaser Fund IV L P is a corporate insider who has filed 5 SEC Form 4 insider transactions across 3 companies since 2009. The most recent filing, for CNCE, was dated Feb 21, 2014. Across all open-market trades the lifetime net is +$19.8M, making them a net buyer over the disclosed history. The firm reports its address in Palo Alto, CA. 13 SEC filings were submitted jointly with YASUNORI KANEKO.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

5

Lifetime Open-Market Net

$19.80M

Filer Profile

Reported Address
125 UNIVERSITY AVE
PALO ALTO, CA 94301
Formerly Known As
Skyline Venture Parters Qualified Purchaser Fund IV L P (2005–2005)
Related Filers
YASUNORI KANEKO — 13 joint filings, latest 2014-10-29
John Gordon Freund — 9 joint filings, latest 2014-10-29
STEPHEN J HOFFMAN — 4 joint filings, latest 2014-03-14
Skyline Venture Partners Qualified Purchaser Fund III, L.P. — 2 joint filings, latest 2009-02-27
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted 10%+ Owner 1,208,920 $8.37 $10.12M $6.30M 1 2014-02-21
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted 10%+ Owner 4,121 — — $14.30M 1 2013-03-27
Oruka Therapeutics, Inc. (ABIO) Delisted 10%+ Owner 38 $28.80 $1.1K -$803.5K 3 2009-06-15

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2014-02-21 CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted Mixed +3,529,644 $6.30M EDGAR
2013-03-27 TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Mixed +6,539,400 $14.30M EDGAR
2009-06-15 Oruka Therapeutics, Inc. (ABIO) Delisted Sell (S) −50,600 -$195.3K EDGAR
2009-06-10 Oruka Therapeutics, Inc. (ABIO) Delisted Sell (S) −149,208 -$608.2K EDGAR
2009-06-03 Oruka Therapeutics, Inc. (ABIO) Delisted Other (J) −342,375 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.